Effects of bone-targeted agents on cancer progression and mortality. (Q38023206)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22752060%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

title

Effects of bone-targeted agents on cancer progression and mortality (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22752060%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22752060%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

Gareth J Morgan

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22752060%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

Philippe Clézardin

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22752060%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

author name string

Robert Coleman

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22752060%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

language of work or name

English

0 references

publication date

2 July 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22752060%20AND%20SRC:MED&resulttype=core&format=json

Journal of the National Cancer Institute

6 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22752060%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

volume

104

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22752060%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

issue

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22752060%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

page(s)

1059-1067

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22752060%20AND%20SRC:MED&resulttype=core&format=json

Anticancer evidence for zoledronic acid across the cancer continuum.

6 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJS263

Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJS263

Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJS263

Anti-tumour activity of bisphosphonates in preclinical models of breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJS263

The hemopoietic stem cell niche versus the microenvironment of the multiple myeloma-tumor initiating cell

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJS263

The role of the bone marrow microenvironment in the pathophysiology of myeloma and its significance in the development of more effective therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJS263

CD8+ T cells regulate bone tumor burden independent of osteoclast resorption

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJS263

Can bisphosphonates improve outcomes in patients with newly diagnosed multiple myeloma?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJS263

American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJS263

Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJS263

Prevention and treatment of bone metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJS263

Molecular mechanisms and clinical applications of angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJS263

Zoledronic acid repolarizes tumour-associated macrophages and inhibits mammary carcinogenesis by targeting the mevalonate pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJS263

Nitrogen-containing bisphosphonates and cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJS263

High phosphoantigen levels in bisphosphonate-treated human breast tumors promote Vgamma9Vdelta2 T-cell chemotaxis and cytotoxicity in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJS263

Long-term follow-up of a prospective, double-blind, placebo-controlled randomized trial of clodronate in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJS263

Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX): secondary outcomes from a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJS263

The bisphosphonate zoledronic acid induces cytotoxicity in human myeloma cell lines with enhancing effects of dexamethasone and thalidomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJS263

Synergistic antimyeloma effects of zoledronate and simvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJS263

Bortezomib and zoledronic acid on angiogenic and vasculogenic activities of bone marrow macrophages in patients with multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJS263

The bisphosphonate zoledronic acid has antimyeloma activity in vivo by inhibition of protein prenylation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJS263

Advances in the biology and treatment of bone disease in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJS263

Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJS263

An open-label, phase 2 trial of denosumab in the treatment of relapsed or plateau-phase multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJS263

Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJS263

Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJS263

Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJS263

A prospective, randomized, placebo-controlled trial of zoledronic acid in bony metastatic bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJS263

Adjuvant docetaxel for node-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJS263

Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJS263

Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJS263

Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJS263

21 January 2018

Identifiers

DOI

10.1093/JNCI/DJS263

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22752060%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

1 reference